Table 3.
Evaluation of diagnoses and treatments: precision, identification, and off-label situationsa.
| Diagnoses | Treatments | Occurrences, n (%) | Precise diagnosis, n (%) | Broad diagnosis, n (%) | Identified treatment, n (%) | Off-label situation, n (%) |
| Bipolar disorder | Sodium valproate | 108 (54.8) | 90 (83.3) | 104 (96.3) | 68 (63.0) | 65 (60.2) |
| Schizophrenia | Sodium valproate | 37 (18.8) | 28 (75.7) | 30 (81.1) | 25 (67.6) | 18 (48.6) |
| Obsessive-compulsive disorder | Venlafaxine | 11 (5.6) | 8 (72.7) | 8 (72.7) | 7 (63.6) | 5 (45.5) |
| Attention-deficit/hyperactivity disorder in adults | Methylphenidate | 9 (4.6) | 8 (88.9) | 8 (88.9) | 5 (55.6) | 5 (55.6) |
| Bipolar disorder | Pramipexole | 6 (3.0) | 4 (66.7) | 4 (66.7) | 4 (66.7) | 2 (33.3) |
| Mood disorders | Topiramate | 6 (3.0) | 1 (16.7) | 3 (50.0) | 4 (66.7) | 3 (50.0) |
| Posttraumatic stress disorder | Venlafaxine | 6 (3.0) | 3 (50.0) | 3 (50.0) | 5 (83.3) | 2 (33.3) |
| Major depressive disorder | Pramipexole | 4 (2.0) | 3 (75.0) | 3 (75.0) | 2 (50.0) | 1 (25.0) |
| Weight loss | Topiramate | 3 (1.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hyperphagia | Topiramate | 3 (1.5) | 2 (66.7) | 2 (66.7) | 0 (0.0) | 0 (0.0) |
| Narcolepsy | Methylphenidate | 1 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neuralgia | Topiramate | 1 (0.5) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| Fibromyalgia | Pramipexole | 1 (0.5) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| Autism spectrum disorder | Methylphenidate | 1 (0.5) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) |
aN=197 system-flagged drug-pathology pairs; n (%) values are calculated within each drug-pathology pair.